Results 121 to 130 of about 89,996 (262)

TRIB3 Is a Hub Gene in Steatohepatitis and Aggravates Lipid Deposition and Inflammation in Hepatocytes

Diabetes, Metabolic Syndrome and Obesity
Wen Xia,1,* Li Xiao,1,* Huan Cheng,1 Yuwei Feng2 1Department of Cardiovascular Medicine, Wuhan No.1 Hospital, Wuhan, Hubei, People’s Republic of China; 2Department of Hepatology with Integrated Traditional Chinese and Western Medicine, Hubei No.3
Xia W, Xiao L, Cheng H, Feng Y
doaj  

Editorial: Adaptive immune regulation of non-alcoholic steatohepatitis (NASH). [PDF]

Front Immunol
Wang H.
europepmc   +1 more source

Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol. [PDF]

BMJ Open
He K, Chen F, Shao R, Jiang W, Gu W, Huang Z, Gan Y, Wang Y, Wu H, Zhao Y, Zhang B, Gao L, Yan X, Yao C, Shen C, Ji P, Wei J, Bian Y, Lu Y, Abuduaini A, Liu L, Li H.   +21 more
europepmc   +1 more source

Mapping Causal Biology: Mendelian Randomization in the Era of Big Data

Med Research, EarlyView.
Mendelian randomization (MR) leverages genetic variants to mitigate confounding biases in causal inference. This review systematically maps MR's methodological evolution, highlights its expanding applications in epidemiology and drug target validation, and outlines future directions for overcoming current biases through dynamic, multi‐omics, and cross ...
Xuanlu Shen, Chunrun Qu, Zeyu Wang, Jinglin Zhou, Hongwei Liu, Yingjie Li, Bowei Liu, Hao Zhang, Nan Zhang, Jingwei Zhang, Quan Cheng   +10 more
wiley   +1 more source

Fibroblast Growth Factor 21 Analogues Improve Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis: An Updated Systematic Review and Meta-Analysis. [PDF]

Int J Hepatol
Naqash M, Tariq A, Shayan S, Sargani SM, Raza MA, Khan NN, Balouch A, Usama RM, Ahmed KAHM.   +8 more
europepmc   +1 more source

Toxicity Differences Between Microplastics and Nanoplastics in Organs: From Molecular Mechanisms to Potential Therapeutic Strategies

Med Research, EarlyView.
This review systematically compares the size‐dependent toxicity of microplastics and nanoplastics in the intestine, liver, kidney, lung, and brain. Particle size determines bioavailability, barrier penetration, and injury mechanisms. Because of their small size and high surface reactivity, NPs readily cross the intestinal epithelium and blood–brain ...
Yixian Cheng, Junjie Chen, Rui Fu, Jiawei Zhang, Jianguang Jia, Wei Wang, Zheng Zhang, Peng Zhang, Haosong Chen, Huake Cao, Gang Li, Weiwei Sheng, Ting Li, Bo Chen, Guodong Cao   +14 more
wiley   +1 more source

Development of a Patient Journey Map for Metabolic Dysfunction-Associated Steatohepatitis: A Comprehensive Assessment of the Patient Journey in North America. [PDF]

J Patient Exp
Garcia DO, Calle RA, Seth A, Norton TD, Lederer DJ, Richardson A, Berg J, Betel M, Chang H, Daniels H, Eskridge W, McIntyre J, Villiotti Madison G, Villiotti T, Sellati R.   +14 more
europepmc   +1 more source

Incomplete Spoiling Correction for 3D T1$$ {T}_1 $$ Mapping

Magnetic Resonance in Medicine, EarlyView.
ABSTRACT Purpose Assess the impact of incomplete spoiling and spatial saturation on T1$$ {T}_1 $$ mapping using the variable flip angle (VFA) spoiled gradient recalled echo sequence (SPGR). Develop a correction for incomplete spoiling that results in an accurate estimate of T1$$ {T}_1 $$, essential for quantitative MRI applications.
Gabriela Belsley, Damian J. Tyler, Matthew D. Robson, Elizabeth M. Tunnicliffe   +3 more
wiley   +1 more source

Depletion of NAT10 in T cells attenuates metabolic dysfunction-associated steatohepatitis in mice. [PDF]

Hepatol Commun
Yang Y, Lu J, Ma M, Zhou J, Wang E, Lu Y, Dai Z, Zhou B, Li Y.   +8 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps

Obesity, EarlyView.
ABSTRACT The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight‐based outcomes but by changes in body composition. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can
Robert L. Dubin, Tierra N. Sanders, Hunter M. Schwab, Steven B. Heymsfield, Frank L. Greenway   +4 more
wiley   +1 more source